<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">73288</article-id><article-id pub-id-type="doi">10.7554/eLife.73288</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Predicting progression free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-98472"><name><surname>Barber</surname><given-names>Paul R</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8595-1141</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-251525"><name><surname>Mustapha</surname><given-names>Rami</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251520"><name><surname>Flores-Borja</surname><given-names>Fabian</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0881-8822</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251521"><name><surname>Alfano</surname><given-names>Giovanna</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251522"><name><surname>Ng</surname><given-names>Kenrick</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-251523"><name><surname>Weitsman</surname><given-names>Gregory</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251524"><name><surname>Dolcetti</surname><given-names>Luigi</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-290207"><name><surname>Suwaidan</surname><given-names>Ali Abdulnabi</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251526"><name><surname>Wong</surname><given-names>Felix</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251527"><name><surname>Vicencio</surname><given-names>Jose M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251528"><name><surname>Galazi</surname><given-names>Myria</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251529"><name><surname>Opzoomer</surname><given-names>James W</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6842-756X</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251530"><name><surname>Arnold</surname><given-names>James N</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-11"/><xref ref-type="other" rid="par-12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-126802"><name><surname>Thavaraj</surname><given-names>Selvam</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5720-7422</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-206992"><name><surname>Kordasti</surname><given-names>Shahram</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0347-4207</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-251531"><name><surname>Doyle</surname><given-names>Jana</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-251532"><name><surname>Greenberg</surname><given-names>Jon</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-251533"><name><surname>Dillon</surname><given-names>Magnus T</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146939"><name><surname>Harrington</surname><given-names>Kevin J</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-251534"><name><surname>Forster</surname><given-names>Martin D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-251535"><name><surname>Coolen</surname><given-names>Anthony C C</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6976-5875</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" corresp="yes" id="author-41742"><name><surname>Ng</surname><given-names>Tony</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3894-5619</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf10"/></contrib><aff id="aff1"><institution content-type="dept">UCL Cancer Institute</institution>, <institution>University College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">Richard Dimbleby Laboratory of Cancer Research</institution>, <institution>King's College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution content-type="dept">Breast Cancer Now Research Unit</institution>, <institution>King's College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff4"><institution content-type="dept">Tumor Immunology Group</institution>, <institution>King's College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff5"><institution content-type="dept">Centre for Oral, Clinical and Translational Sciences</institution>, <institution>King's College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff6"><institution content-type="dept">Systems Cancer Immunology</institution>, <institution>King's College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff7"><institution>Daichii Sankyo Incorporated</institution>, <addr-line><named-content content-type="city">New Jersey</named-content></addr-line>, <country>United States</country></aff><aff id="aff8"><institution>Institute of Cancer Research</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff9"><institution content-type="dept">Institute for Mathematical and Molecular Biomedicine</institution>, <institution>King's College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-71715"><name><surname>Grandis</surname><given-names>Jennifer</given-names></name><role>Reviewing editor</role><aff><institution>University of California, San Francisco</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>tony.ng@kcl.ac.uk</email> (TN);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>23</day><month>12</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e73288</elocation-id><history><date date-type="received"><day>24</day><month>08</month><year>2021</year></date><date date-type="accepted"><day>22</day><month>12</month><year>2022</year></date></history><permissions><copyright-statement>Â© 2022, Barber et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Barber et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-73288-v1.pdf"/><abstract><p><bold>Background:</bold> Advanced Head and Neck Squamous Cell Cancer (HNSCC) is associated with a poor prognosis, and biomarkers that predict response to treatment are highly desirable. The primary aim was to predict Progression Free Survival (PFS) with a multivariate risk prediction model.</p> <p><bold>Methods:</bold> Experimental covariates were derived from blood samples of 56 HNSCC patients which were prospectively obtained within a Phase 2 clinical trial (NCT02633800) at baseline and after the first treatment cycle of combined platinum-based chemotherapy with cetuximab treatment. Clinical and experimental covariates were selected by Bayesian multivariate regression to form risk scores to predict Progression Free Survival (PFS).</p> <p><bold>Results:</bold> A 'baseline' and a 'combined' risk prediction model were generated, each of which featuring clinical and experimental covariates. The baseline risk signature has 3 covariates and was strongly driven by baseline percentage of CD33<sup>+</sup>CD14<sup>+</sup>HLADR<sup>high</sup> monocytes. The combined signature has 6 covariates, also featuring baseline CD33<sup>+</sup>CD14<sup>+</sup>HLADR<sup>high</sup> monocytes but is strongly driven by on-treatment relative change of CD8<sup>+</sup> central memory T cells percentages. The combined model has a higher predictive power than the baseline model and was successfully validated to predict therapeutic response in an independent cohort of 9 patients from an additional Phase 2 trial (NCT03494322) assessing the addition of avelumab to cetuximab treatment in HNSCC. We identified tissue counterparts for the immune cells driving the models, using imaging mass cytometry, that specifically colocalized at the tissue level and correlated with outcome.</p> <p><bold>Conclusions:</bold> This immune-based combined multimodality signature, obtained through longitudinal peripheral blood monitoring and validated in an independent cohort, presents a novel means of predicting response early on during the treatment course.</p> <p><bold>Funding:</bold> Daiichi Sankyo Inc, Cancer Research UK, EU IMI2 IMMUCAN, UK Medical Research Council, European Research Council (335326), Merck Serono. Cancer Research Institute, National Institute for Health Research, Guy's and St Thomas' NHS Foundation Trust and The Institute of Cancer Research</p> <p><bold>Clinical trial number: </bold>NCT02633800.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>Early Detection Award C7675/A29313</award-id><principal-award-recipient><name><surname>Barber</surname><given-names>Paul R</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000650</institution-id><institution>Institute of Cancer Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Dillon</surname><given-names>Magnus T</given-names></name><name><surname>Harrington</surname><given-names>Kevin J</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004941</institution-id><institution>Guy's and St Thomas' NHS Foundation Trust</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Thavaraj</surname><given-names>Selvam</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Mustapha</surname><given-names>Rami</given-names></name><name><surname>Weitsman</surname><given-names>Gregory</given-names></name><name><surname>Kordasti</surname><given-names>Shahram</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>City of London Centre CTRQQR-2021\100004</award-id><principal-award-recipient><name><surname>Barber</surname><given-names>Paul R</given-names></name><name><surname>Ng</surname><given-names>Tony</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>Clinical Fellowship Awards</award-id><principal-award-recipient><name><surname>Ng</surname><given-names>Kenrick</given-names></name><name><surname>Suwaidan</surname><given-names>Ali Abdulnabi</given-names></name><name><surname>Galazi</surname><given-names>Myria</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>Early Detection and Diagnosis Committee Project grant</award-id><principal-award-recipient><name><surname>Alfano</surname><given-names>Giovanna</given-names></name><name><surname>Vicencio</surname><given-names>Jose M</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100020098</institution-id><institution>Innovative Health Initiative</institution></institution-wrap></funding-source><award-id>EU IMI2 IMMUCAN (Grant agreement number 821558)</award-id><principal-award-recipient><name><surname>Dolcetti</surname><given-names>Luigi</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/N013700/1</award-id><principal-award-recipient><name><surname>Opzoomer</surname><given-names>James W</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/N013700/1</award-id><principal-award-recipient><name><surname>Wong</surname><given-names>Felix</given-names></name></principal-award-recipient></award-group><award-group id="par-11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>DCRPGF\100009</award-id><principal-award-recipient><name><surname>Arnold</surname><given-names>James N</given-names></name></principal-award-recipient></award-group><award-group id="par-12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000884</institution-id><institution>Cancer Research Institute</institution></institution-wrap></funding-source><award-id>Wade F.B. Thompson CLIP grant (CRI3645)</award-id><principal-award-recipient><name><surname>Arnold</surname><given-names>James N</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Paul R Barber, is a shareholder of Nano Clinical Ltd.</p></fn><fn fn-type="conflict" id="conf3"><p>Kenrick Ng, has received honoraria from Pfizer, GSK/Tesaro and Boheringer Ingleheim, and has had travel/accommodation/expenses paid for by Tesaro..</p></fn><fn fn-type="conflict" id="conf4"><p>Shahram Kordasti, has received research funding in the form of a grant from Novartis and Celgene.</p></fn><fn fn-type="conflict" id="conf5"><p>Jana Doyle, is in employment with Daichii Sankyo, and has stock and other ownership interests, research funding within Daichii Sankyo and has had travel/accommodation/expenses paid for by Daichii Sankyo.</p></fn><fn fn-type="conflict" id="conf6"><p>Jon Greenberg, is in employment with Daichii Sankyo, and has stock and other ownership interests, research funding within Daichii Sankyo and has had travel/accommodation/expenses paid for by Daichii Sankyo.</p></fn><fn fn-type="conflict" id="conf7"><p>Kevin J Harrington, has received honoraria from Amgen; Arch Oncology; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Codiak; Inzen; Merck; MSD; Pfizer; Replimune and is on a speakers' bureau for Amgen, AstraZeneca; Bristol-Myers Squibb; Merck, MSD; Pfizer. KH has also received research funding from AstraZeneca, Boehringer-Ingelheim, MSD and Replimune..</p></fn><fn fn-type="conflict" id="conf8"><p>Martin D Forster, has received institutional research funding from AstraZeneca, Boehringer-Ingelheim, Merck and MSD and serves in a consulting or advisory role to Achilles, Astrazeneca, Bayer, Bristol-Myers Squibb, Celgene, Guardant Health, Merck, MSD, Nanobiotix, Novartis, Oxford VacMedix, Pfizer, Roche, Takeda, UltraHuman.</p></fn><fn fn-type="conflict" id="conf9"><p>Anthony C C Coolen, has stock and other ownership interests with Saddle Point Science Limited..</p></fn><fn fn-type="conflict" id="conf10"><p>Tony Ng, has received research funding from Astrazeneca and Daichii Sankyo. TN is a founder and shareholder in Nano Clinical Ltd, and PRB is a shareholder..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Written informed consent was obtained for all patients who participated in the Phase 2 clinical trial. Approval was obtained from ethics committees (Research Ethics Committee reference: 15/LO/1670). Approval to procure and process a separate cohort of blood samples from patients at risk of developing lung cancer was also obtained (IRAS ID: 261766).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The data generated in this study and used for multivariate modelling are available from the UCL repository: https://doi.org/10.5522/04/16566207.v1</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Paul BarberPaul Barber</collab><collab>Fabian Flores-Borja</collab><collab>Giovanna Alfano</collab><collab>Kenrick Ng</collab><collab>Gregory Weitsman</collab><collab>Luigi Dolcetti</collab><collab>Rami Mustapha</collab><collab>Felix Wong</collab><collab>Jose M Vicencio BustamanteJose M Vicencio Bustamante</collab><collab>Myria Galazi</collab><collab>James Opzoomer</collab><collab>James Arnold</collab><collab>Shahram Kordasti</collab><collab>Jana Doyle</collab><collab>Jon Greenberg</collab><collab>Magnus Dillon</collab><collab>Kevin Harrington</collab><collab>Martin ForsterMartin Forster</collab><collab>Ton Coolen</collab><collab>Tony Ng</collab></person-group><year iso-8601-date="2021">2021</year><source>Head and Neck Cancer Multivariate Blood Data</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5522/04/16566207.v1">https://doi.org/10.5522/04/16566207.v1</ext-link><comment>UCL Research Data Repository, doi:10.5522/04/16566207.v1</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-73288-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>